A trio of studies being published today in the journals Science and Cell describes advances toward the development of an HIV vaccine. The three study teams all demonstrated techniques for stimulating animal cells to produce antibodies that either could stop HIV from infecting human cells in the laboratory or had the potential to evolve into such antibodies. Each of the research teams received funding from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
P Dosenovic et al. Immunization for HIV-1 broadly neutralizing antibodies in human Ig knockin mice. Cell DOI: 10.1016/j.cell.2015.06.003 (2015).
NIAID Director Anthony S. Fauci, M.D., and NIAID Vaccine Research Center Director John R. Mascola, M.D., are available for interviews.
To schedule interviews, please contact Laura S. Leifman, (301) 402-1663, [email protected].
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health ®